301080 logo

Acrobiosystems Co.,Ltd.SZSE:301080 Stock Report

Market Cap CN¥7.1b
Share Price
CN¥57.00
My Fair Value
CN¥50
14.3% overvalued intrinsic discount
1Y144.9%
7D0.6%
Portfolio Value
View

Acrobiosystems Co.,Ltd.

SZSE:301080 Stock Report

Market Cap: CN¥7.1b

AcrobiosystemsLtd (301080) Stock Overview

Engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and scientific research institutions. More details

301080 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance2/6
Financial Health5/6
Dividends2/6

301080 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Acrobiosystems Co.,Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for AcrobiosystemsLtd
Historical stock prices
Current Share PriceCN¥57.00
52 Week HighCN¥61.20
52 Week LowCN¥22.36
Beta1.01
1 Month Change8.12%
3 Month Change57.52%
1 Year Change144.94%
3 Year Change-21.79%
5 Year Changen/a
Change since IPO-29.10%

Recent News & Updates

Recent updates

Acrobiosystems Co.,Ltd. (SZSE:301080) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable

Feb 12
Acrobiosystems Co.,Ltd. (SZSE:301080) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable

AcrobiosystemsLtd's (SZSE:301080) Anemic Earnings Might Be Worse Than You Think

Nov 06
AcrobiosystemsLtd's (SZSE:301080) Anemic Earnings Might Be Worse Than You Think

Investors Appear Satisfied With Acrobiosystems Co.,Ltd.'s (SZSE:301080) Prospects As Shares Rocket 27%

Oct 01
Investors Appear Satisfied With Acrobiosystems Co.,Ltd.'s (SZSE:301080) Prospects As Shares Rocket 27%

Why We're Not Concerned About Acrobiosystems Co.,Ltd.'s (SZSE:301080) Share Price

Jul 15
Why We're Not Concerned About Acrobiosystems Co.,Ltd.'s (SZSE:301080) Share Price

AcrobiosystemsLtd's (SZSE:301080) Weak Earnings Might Be Worse Than They Appear

May 02
AcrobiosystemsLtd's (SZSE:301080) Weak Earnings Might Be Worse Than They Appear

Shareholder Returns

301080CN BiotechsCN Market
7D0.6%2.9%4.3%
1Y144.9%42.6%50.6%

Return vs Industry: 301080 exceeded the CN Biotechs industry which returned 42.6% over the past year.

Return vs Market: 301080 exceeded the CN Market which returned 50.6% over the past year.

Price Volatility

Is 301080's price volatile compared to industry and market?
301080 volatility
301080 Average Weekly Movement7.7%
Biotechs Industry Average Movement6.2%
Market Average Movement4.9%
10% most volatile stocks in CN Market8.6%
10% least volatile stocks in CN Market2.8%

Stable Share Price: 301080's share price has been volatile over the past 3 months compared to the CN market.

Volatility Over Time: 301080's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

FoundedEmployeesCEOWebsite
2010869Yiding Chenwww.acrobiosystems.cn

Acrobiosystems Co.,Ltd. engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and scientific research institutions. The company has a collaboration with Diagnostic Biochips Inc for neurological drug discovery and commercialization.

Acrobiosystems Co.,Ltd. Fundamentals Summary

How do AcrobiosystemsLtd's earnings and revenue compare to its market cap?
301080 fundamental statistics
Market capCN¥7.10b
Earnings (TTM)CN¥150.94m
Revenue (TTM)CN¥732.99m
45.2x
P/E Ratio
9.3x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
301080 income statement (TTM)
RevenueCN¥732.99m
Cost of RevenueCN¥115.28m
Gross ProfitCN¥617.71m
Other ExpensesCN¥466.77m
EarningsCN¥150.94m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)1.26
Gross Margin84.27%
Net Profit Margin20.59%
Debt/Equity Ratio1.4%

How did 301080 perform over the long term?

See historical performance and comparison

Dividends

1.0%
Current Dividend Yield
32%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/26 15:59
End of Day Share Price 2025/08/26 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Acrobiosystems Co.,Ltd. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yuan GaoChina International Capital Corporation Limited
Zhu ChenCitic Securities Co., Ltd.
Kai WangCitic Securities Co., Ltd.